Gland Pharma receives USFDA tentative approval for Latanoprostene Bunod Ophthalmic Solution 0 24.07.2024 07:39 Business Standard Gland Pharma has received tentative approval from the United States Food and Drug Administration (USFDA) for Latanoprostene Bunod Ophthalmic Solution, 0.024%. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа
